Cargando…
COVACTA trial raises questions about tocilizumab's benefit in COVID-19
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480990/ https://www.ncbi.nlm.nih.gov/pubmed/32929415 http://dx.doi.org/10.1016/S2665-9913(20)30313-1 |
| _version_ | 1783580511322505216 |
|---|---|
| author | Furlow, Bryant |
| author_facet | Furlow, Bryant |
| author_sort | Furlow, Bryant |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7480990 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74809902020-09-10 COVACTA trial raises questions about tocilizumab's benefit in COVID-19 Furlow, Bryant Lancet Rheumatol News Elsevier Ltd. 2020-10 2020-09-09 /pmc/articles/PMC7480990/ /pubmed/32929415 http://dx.doi.org/10.1016/S2665-9913(20)30313-1 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | News Furlow, Bryant COVACTA trial raises questions about tocilizumab's benefit in COVID-19 |
| title | COVACTA trial raises questions about tocilizumab's benefit in COVID-19 |
| title_full | COVACTA trial raises questions about tocilizumab's benefit in COVID-19 |
| title_fullStr | COVACTA trial raises questions about tocilizumab's benefit in COVID-19 |
| title_full_unstemmed | COVACTA trial raises questions about tocilizumab's benefit in COVID-19 |
| title_short | COVACTA trial raises questions about tocilizumab's benefit in COVID-19 |
| title_sort | covacta trial raises questions about tocilizumab's benefit in covid-19 |
| topic | News |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480990/ https://www.ncbi.nlm.nih.gov/pubmed/32929415 http://dx.doi.org/10.1016/S2665-9913(20)30313-1 |
| work_keys_str_mv | AT furlowbryant covactatrialraisesquestionsabouttocilizumabsbenefitincovid19 |